SCHEDULE 13G/A: Nantahala Capital Management Discloses 5.73% Stake in Cellectar Biosciences

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 5.73% in Cellectar Biosciences, Inc. as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 2,507,125 shares of Cellectar Biosciences, Inc. common stock.
• This ownership represents 5.73% of the total outstanding common stock of Cellectar Biosciences, Inc.
• The reported shares include 2,507,125 shares that may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC is classified as an Investment Adviser (IA), while Wilmot B. Harkey and Daniel Mack are classified as Control Persons (HC).
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. While the presence of an institutional investor can be seen as a slight positive, the filing itself is primarily informational and compliance-driven, not indicative of specific company performance or strategic shifts.

Positives

• The disclosure of a significant institutional holding by Nantahala Capital Management may signal confidence from a professional investment firm in Cellectar Biosciences.
• The holding includes shares acquirable via warrants, indicating a potential long-term interest or strategic position.

Risks

• The document itself does not detail specific risks related to Cellectar Biosciences, Inc. beyond the inherent market risks associated with holding common stock and warrants.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Cellectar Biosciences, Inc.'s future performance or outlook.

Industry Context

This filing is a routine disclosure of a significant ownership stake by an institutional investor in a biotechnology company. Such disclosures provide transparency regarding major shareholders but do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence investor sentiment and potentially provide insights into institutional confidence in the company.

Key Dates

Keywords

Cellectar Biosciences, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Investment Adviser